Subscribe to the newsletterForward | Contact | www.lyonbiopole.com   January 2013
 
A LA UNE
From 24th to 26th March 2013 - Lyonbiopole invites you at BIOVISION, the World Life Sciences Forum, in Lyon

The 8th edition of BIOVISION gathering representatives of civil society, scientists, industry and policy makers to discuss key global issues of health, food and environment. The Forum will provide a new organization around three moments: the scientific conferences, BIOVISION Catalyzer to promote collaborative projects and BIOVISION Investor Conference to favour meetings between Biotech, Pharma and private and public investors.

To register: http://www.biovision.org/
For more information on Investor Conference: Isabelle Scarabin, Economic and International Affairs Director - isabelle.scarabin@lyonbiopole.com
To present a project at BIOVISION Catalyzer: Sarah Crochon, Innovation Project Manager -  sarah.crochon@lyonbiopole.com

Learn more



ZOOM SUR
POXEL

December 18, Poxel raised € 13 million to continue the to Progress Imeglimin Development  to Treat Type 2 diabetes. Poxel, founded in 2009, is a biopharmaceutical company developing innovative first-in-class drugs, with a primary focus on Type 2 diabetes. The company develops drug candidates to clinical proof-of-concept before seeking pharmaceutical industry partners.

Learn more



A LA UNE
12/13/2012 - Succes for the 4th Conference on Nosocomial Infections

This 4th edition was held in Lyon on December 13th. The theme "Nosocomial Pathogenesis" was that of the pathogenesis and host response in the nosocomial infection. This fourth edition was attended by 130 people, a large succes.
Contact: Sarah Crochon, Innovation Project Manager, Sepsis program - sarah.crochon@lyonbiopole.com

Learn more


01/16-18/2013 - Come back on the biotechnology workshop during the 41st International Congress on Intensive Care Medicine

For the second year running, Lyonbiopole trough its Sepsis Program, organized a biotechnology workshop during the 41st International Congress on Intensive Care Medicine (SRLF, January 16-18 2013, Paris).
As a major concern for intensive care units, this workshop was focused on risk and therapeutic management of patients against bacterial colonization and gathered over forty participants around three conferences: " Imported multiresistant bacteria: what consequences?» presented by Dr. Jean-Ralph Zahar (Hôpital Necker, Paris)," What isolation for ICU patients? What are the benefits? What are the risks? " by Professor Christian Brun-Buisson (Hôpital Henri Mondor, Créteil) and " Acquired Pneumonia in mechanically ventilated patients: what therapeutic management? " presented by Professor Jean Chastre (Groupe Hospitalier Pitié-Salpêtrière, Paris). The workshop was moderated by Professor Jean-François Timsit (CHU, Grenoble).

Contact : Sarah Crochon, Innovation Project Manager, Sepsis program - sarah.crochon@lyonbiopole.com

Learn more


02/05-06/2013 - Accinov invite you to attend to the 2013 PDA Europe conference: «Modern biopharmaceutical Manufcaturing»

As a speaker, Accinov is pleased to inform you that The Parenteral Drug Association will hold a conference in Lyon. Entitled “Modern biopharmaceutical Manufacturing”, this year’s program will cover practical approaches for the challenges in development and manufacturing of biopharmaceutical and biotechnological derived products in the current GMP environment. International experts will present the latest practices, methods and share their experiences.
Register now and find the agenda of the day on PDA website. Join us during this event scheduled on 05thFebruary at Radisson Blu Hotel Lyon.
Contact: Stephanie Colloud, Accinov Manager - stephanie.colloud@accinov.com

Learn more


03/21-22/2013 - 8th Scientigic Meeting of CLARA, Lyon

The 8th Scientific Meeting of CLARA cancer cluster will take place on 21 and 22 March 2013 Champfleuri, Champagne-au-Mont-d'Or.
Program renowned speakers: Hans Clevers, Institute Ubrecht, Netherlands, Peter Kapitein, Amsterdam, Netherlands - Patient Voice: The Vision for the 21st Century, Elaine Mardis, Genome Institute - University of Washington, St. Louis, USA and Rolf Stahel, University Hospital Zurich, Switzerland ... and a round table, six others sessions, poster presentations and communications Flash.

Contact: Amaury Martin, General Secretary - amartin@canceropole-clara.com

Learn more


BIO Chicago, April 2013 - 21 exhibiting companies from Rhone-Alpes hosted on the Lyonbiopole's booth

Once again this year, the Rhone-Alpes biotech sector will be strongly present during the new edition of BIO 2013 that will be held in Chicago from April 22nd to 25th.
Thanks to the support of the Rhone-Alpes Region, Greater Lyon and the Grenoble Alpes-Metropole and in partnership with the Lyon Chamber of Commerce and UbiFrance, Lyonbiopole will host 21 SMBs on its 775 sq.ft booth on the French Pavilion: Alize Pharma; Adocia; Alaxia; Calixar; CAPEVAL; ClinInfo, The Cosmo Company; Cynbiose; Erytech Pharma; Eveon; Fab'entech; Flamel; Imaxio; ImmunID; Indicia; Metabolys; OncoTherapy Science; Px Therapeutics; Synthelis; TransCure Biosciences.
Furthermore, Lyonbiopole will also organized the 7th edition of the Fast Track R&D Parterning with France, on Monday, April 22nd, as well as a session within the official program of BIO, an "International Market Briefings Track" on the topic"acCInov: A Unique Regulatory and Technological Environment Dedicated to Biomanufacturing in France ", on Wednesday, April 24th.
Contact : Kevin Romani, International Project Manager - kevin.romani@lyonbiopole.com

Learn more



AGENDA
BioPartnering North America 2013
From 24 to 27 february 2013, Vancouver - Canada
Bio Europe Spring
From 11 to 13 march 2013, Barcelona - Spain
The 8th Scientific Days of CLARA
From 21 to 22 march 2013, Lyon - France
The 8th edition of BIOVISION World life sciences Forum
From 24 to 26 march 2013, Lyon - France
BIO Chicago 2013
Du 22 au 25 avril 2013, Chicago (IL) - USA
15th edition of BIOFORUM-BIOTECH
From 29 to 31 may 2013 - Shanghai - China
 
A LA UNE
16th “Single Inter-ministry funding” FUI call for projects

The 16th FUI call for projects will be launched in March, 2013. To be eligible to this call your project must be a collaborative R&D project accredited by a Competitiveness Cluster and involving at least 2 companies and one laboratory/research center with R&D activities in France. Lyonbiopole helps you to build your projects and studies your accreditation requests. For these purpose, a letter of intent must be send to Lyonbiopole before February 22, 2013.
Contact: Claudia Chagneau, R&D Projects Manager - claudia.chagneau@lyonbiopole.com

Learn more


01/02/2013 - HIVERA  joint  transnational call 2013 open

Eranet HIVERA program, coordinated by the ANRS and supported by the European Commission launched on 2 January 2013, its second call for transnational projects for European research on HIV / AIDS. At least three countries, HIVERA partners must be involved in the project: Germany, Estonia, France, Portugal, Romania, Flemish Region. The topics covered include: "Advanced research on reservoirs and cure", "Research on prevention and treatment." The projects may involve basic research, clinical research (excluding clinical trials), research in health economics and SHS. A partnership event is held in Paris January 25, 2013. Deadline for submission: April 13, 2013. Lyonbiopole supports you for your project setting-up thanks to its PPTE program.
Contact: Emilie Romeo, Project manager – emilie.romeo@lyonbiopole.com

Learn more


12/21/2012 - 7th call for project of the CIP ICT PSP open
 



The CIP ICT PSP (program innovation and competitiveness using ICT in support of public policies) opened its 7th Call for Proposals on December 21, 2012 (deadline: 14 May 2013) for projects to promote pilot services in various fields including "ICT for health, aging well and inclusion", "Open for innovation and other objective measures." This call is an opportunity for the Commission to test a new instrument: the PPI (Public Procurement for Innovative solutions). It is also an occasion in the "open innovation" call (without thematic set) for innovative applications.  Lyonbiopole supports you in setting-up your project through its PPTE program.
Contact: Emilie Romeo, Project manageremilie.romeo@lyonbiopole.com

Learn more


12/2012 - 10th Eurostars call for projects is open

This European program aims at funding collaborative projects of European innovative SMBs of all technological sectors. Deadline for application is planned on April 4th 2013. Lyonbiopole can support you to build your EU project thanks to its PPTE program.
Contact: Emilie Romeo, Project Manager - emilie.romeo@lyonbiopole.com

Learn more


12/2012 - 8th Call IMI open

The program IMI opened its 8th call for proposals on 18 December 2012. 2 topics dealing with Antimicrobial resistance "NewDrugs4BadBugs (ND4BB)"; other subjects "Taxonomy of disease, two topics: Rheumatoid arthritis & lupus - Alzheimer's disease & Parkinson's disease", "European induced pluripotent stem cell bank." Date for applications is 19 March 2013. Lyonbiopole offers you to benefit from its PPTE program and assists you in setting up European projects. We remind you that the European Commission is currently developing its new program of research and innovation for the 2014-2020 period called Horizon 2020. No FP7 call will be launched in 2013, the new calls will be launched H2020 late 2013 - early 2014.
Contact: Emilie Romeo, Project Manager - emilie.romeo@lyonbiopole.com

Learn more



A LA UNE
12/04/2012 - Operational implementation and launch of the first R&D programs for BIOASTER, Technological Resarch Institute

On November 6th, the board of directors formalized the launch of the first phase of the research and development programs of the Technological Research Institute BIOASTER, as well as the deployment of its technology centers. Dedicated to infectious diseases and microbiology, BIOASTER ensures optimal chain research and innovation through R&D disciplines.
Contact: Jacques Berger, General Manager - jacques.berger@bioaster.com

Learn more


01/01/2013 - Launch of International Centre for Research in Infectious Diseases CIRI

The International Centre for Research in Infectious Diseases (CIRI) was officially launched on January 1, 2013. This center gathers 20 academic research teams from Lyon and aims to attract new teams to be one of the major European Centers of Excellence in basic and translational research on infectious diseases. CIRI is located on campus Charles Mérieux in Lyon Gerland and collaborates with Lyonbiopole and BIOASTER.

Contact: François-Loic Cosset, CIRI General Manager - francois-loic.cosset@ens-lyon.fr

Learn more


01/23/2013 - Lyonbiopole and its partners receive an expert of the life sciences market in China in the bioXclusters frame.  



Within the framework of the European project bioXclusters and "Mobility Clusters"program  funded by the Rhône-Alpes region and managed by ERAI, Lyonbiopole welcomed on January 2013 21, 22 and 23 an expert of the Chinese life sciences sector: Mr. Gao Rong-Hui, CEO of G-Med Consulting firm specialized in life sciences, and Advisor of Shanghai Zhangjiang Pharma Valley, the largest bio-cluster in China bringing about 2000 companies. On this occasion, a workshop "How to access to the Chinese market" gathering 15 member companies of the cluster in the presence of Simon Gudin, cluster’s representative in Shanghai and Axten, for the regulatory aspects. Individual appointments were then offered to participating companies.
Contact: Emilie Romeo, Project Manager - emilie.romeo@lyonbiopole.com

Learn more


01/23/2013 - Lyonbiopole and Clara are joining forces

Clara and Lyonbiopole agree to combine their respective strengths to enhance development and transfer of knowledge from research to clinical applications and business world. Relying on the skills and strengths of each structure, the alliance will bring together the emerging practices and labeling of R&D projects and to develop a one-stop service for innovative companies and researchers to accompany them in their optimal development.

Contact: Isabelle Scarabin, Economic and International Affairs Director - isabelle.scarabin@lyonbiopole.com

Learn more


01/2013 - Lyonbiopole supports you in your internationalization: the ITPP for your partner search

The International Technological Partnership Program (ITPP) aims to encourage business growth by providing a technical and financial support for the search of strategic partners at international and european level. This program is financed by the Rhone-Alpes region in the framework of the Lyonbiopole's International Development Plan (IDP) and it allowed to support 10 companies in 2012. In 2013, Lyonbiopole maintains this program again and is ready to support its SMBs abroad.
Contact: Kevin Romani, International Project Manager - kevin.romani@lyonbiopole.com
 

Learn more


12/16/2012 - Creation of a leading European biotechnology company in vaccines and antibodies: Valvena

Vivalis and Intercell AG merged to form Valneva, with headquarters in Lyon (France), which will be listed on the regulated market of NYSE Euronext in Paris and the Vienna Stock Exchange.

Learn more


12/17/2012 - Innate Pharma SA : first patient treated in the EffiKIR trial.

Innate Pharma SA, the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases announces that the first patient was treated in the EffiKIR trial. EffiKIR is a double-blind placebo-controlled randomized Phase II trial of IPH2102/BMS-986015 as maintenance treatment in elderly patients with Acute Myeloid Leukemia (AML) in first complete remission.

Learn more


12/17/2012 - Imaxio sign an option agreement license with Merial for developing a vaccine in animal health

This agreement aims to develop a vaccine in animal health on the basis of the technology of immunogenic IMX313 Imaxio. Merial evaluates internal technology IMX313 of Imaxio for 12 to 18 months and consider depending on the results, the signing of a license agreement.

Learn more


01/03/2013 - Alize Pharma announces the launch of the research program PREMAG

This collaborative project of nearly 4 million is to expand the therapeutic potential of AZP-531, analogous to UAG Alize Pharma, with indications of cardioprotection and cachexia.

Learn more

 
© Lyonbiopole 2019  |  CREDITS  |  LEGAL NOTICE  |